MGO One Seven LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 26.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 7,745 shares of the medical research company’s stock after purchasing an additional 1,615 shares during the period. MGO One Seven LLC’s holdings in Thermo Fisher Scientific were worth $5,229,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently made changes to their positions in the business. Americana Partners LLC grew its holdings in Thermo Fisher Scientific by 0.7% during the third quarter. Americana Partners LLC now owns 81,349 shares of the medical research company’s stock valued at $54,914,000 after purchasing an additional 566 shares during the period. Aprio Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 22.0% during the third quarter. Aprio Wealth Management LLC now owns 2,192 shares of the medical research company’s stock valued at $1,480,000 after buying an additional 396 shares during the last quarter. Avestar Capital LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth $2,901,000. Modera Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 12.3% in the third quarter. Modera Wealth Management LLC now owns 4,584 shares of the medical research company’s stock worth $3,094,000 after buying an additional 502 shares in the last quarter. Finally, Greenup Street Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific during the third quarter worth $204,000. Institutional investors own 89.23% of the company’s stock.
Thermo Fisher Scientific Trading Down 2.1%
TMO stock opened at $682.43 on Tuesday. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $711.85. The stock has a market capitalization of $252.33 billion, a price-to-earnings ratio of 35.99, a price-to-earnings-growth ratio of 2.87 and a beta of 0.87. The firm’s fifty day simple moving average is $655.94 and its two-hundred day simple moving average is $553.32.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The business had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same quarter last year, the firm earned $5.79 earnings per share. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current year.
Insider Transactions at Thermo Fisher Scientific
In related news, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 2,831 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $706.45, for a total value of $1,999,959.95. Following the completion of the transaction, the vice president owned 11,560 shares in the company, valued at $8,166,562. This represents a 19.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 76,199 shares of company stock valued at $45,896,780 over the last 90 days. 0.33% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
TMO has been the subject of several research analyst reports. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Guggenheim started coverage on shares of Thermo Fisher Scientific in a report on Thursday, October 15th. They set a “buy” rating for the company. Royal Bank Of Canada raised their price objective on Thermo Fisher Scientific from $580.00 to $730.00 and gave the company a “sector perform” rating in a research report on Thursday, October 22nd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $720.00 target price on shares of Thermo Fisher Scientific in a report on Friday, September 25th. Finally, HSBC upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 1st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $689.10.
Get Our Latest Stock Analysis on Thermo Fisher Scientific
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.
Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.
Featured Stories
- Five stocks we like better than Thermo Fisher Scientific
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
